A Study of Carbon-14-Labelled [14C] LY3556050 in Healthy Male Participants

Eli Lilly and Company7 enrolled

Overview

The main purpose of this study is to evaluate how much of the study drug (LY3556050), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air in healthy male participants. The study will also measure how much of the study drug gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 58 days including the screening period.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Healthy

Interventions

[14C]-LY3556050DRUG

Administered orally

Eligibility

Sex: MALEMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Male participants who are overtly healthy as determined by medical evaluation * Have a body mass index of 18.0 to 32.0 kilograms per meter squared (kg/m²), inclusive * Males who agree to use highly effective or effective methods of contraception Exclusion Criteria: * Have known allergies to LY3556050, related compounds, or any components of the formulation of LY3556050, or history of significant atopy * Have clinically significant abnormal BP and/or pulse rate as determined by the investigator * Have had exposure to significant diagnostic, therapeutic, or employment-related radiation within 12 months prior to dosing

Locations (1)

LabCorp CRU, Inc.

Madison, Wisconsin, United States

Outcomes

Primary Outcomes

Urinary Excretion of LY3556050 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered